Selected research
Market Structure
Global Muscarinic Acetylcholine Receptor M4 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Muscarinic Acetylcholine Receptor M4 market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Muscarinic Acetylcholine Receptor M4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Muscarinic Acetylcholine Receptor M4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Muscarinic Acetylcholine Receptor M4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Muscarinic Acetylcholine Receptor M4 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Muscarinic Acetylcholine Receptor M4 include Sumitomo Dainippon Pharma Co Ltd, AstraZeneca Plc, NeuroHealing Pharmaceuticals Inc, Karuna Pharmaceuticals Inc, Heptares Therapeutics Ltd and Anavex Life Sciences Corp, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Muscarinic Acetylcholine Receptor M4 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Muscarinic Acetylcholine Receptor M4 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Muscarinic Acetylcholine Receptor M4 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Muscarinic Acetylcholine Receptor M4 market size, projected growth trends, production technologies, key applications, and end-use industries.
Muscarinic Acetylcholine Receptor M4 Segment by Company
Sumitomo Dainippon Pharma Co Ltd
AstraZeneca Plc
NeuroHealing Pharmaceuticals Inc
Karuna Pharmaceuticals Inc
Heptares Therapeutics Ltd
Anavex Life Sciences Corp
Muscarinic Acetylcholine Receptor M4 Segment by Type
Tropicamide
VU-0467154
ANAVEX-273
Others
Muscarinic Acetylcholine Receptor M4 Segment by Application
Amnesia
Cognitive Disorders
Psychosis
Others
Muscarinic Acetylcholine Receptor M4 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Muscarinic Acetylcholine Receptor M4 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Muscarinic Acetylcholine Receptor M4 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Muscarinic Acetylcholine Receptor M4.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Muscarinic Acetylcholine Receptor M4 market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Muscarinic Acetylcholine Receptor M4 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Muscarinic Acetylcholine Receptor M4 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Muscarinic Acetylcholine Receptor M4 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tropicamide
- VU-0467154
- ANAVEX-273
- Others
Applications
- Amnesia
- Cognitive Disorders
- Psychosis
- Others
Companies covered
- Sumitomo Dainippon Pharma Co Ltd
- AstraZeneca Plc
- NeuroHealing Pharmaceuticals Inc
- Karuna Pharmaceuticals Inc
- Heptares Therapeutics Ltd
- Anavex Life Sciences Corp
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Muscarinic Acetylcholine Receptor M4 Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Muscarinic Acetylcholine Receptor M4 Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Muscarinic Acetylcholine Receptor M4 Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Muscarinic Acetylcholine Receptor M4 Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Muscarinic Acetylcholine Receptor M4 Market Dynamics
- 2.1 Muscarinic Acetylcholine Receptor M4 Industry Trends
- 2.2 Muscarinic Acetylcholine Receptor M4 Industry Drivers
- 2.3 Muscarinic Acetylcholine Receptor M4 Industry Opportunities and Challenges
- 2.4 Muscarinic Acetylcholine Receptor M4 Industry Restraints
3 Muscarinic Acetylcholine Receptor M4 Market by Manufacturers
- 3.1 Global Muscarinic Acetylcholine Receptor M4 Revenue by Manufacturers (2021-2026)
- 3.2 Global Muscarinic Acetylcholine Receptor M4 Sales by Manufacturers (2021-2026)
- 3.3 Global Muscarinic Acetylcholine Receptor M4 Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Muscarinic Acetylcholine Receptor M4 Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Muscarinic Acetylcholine Receptor M4 Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Muscarinic Acetylcholine Receptor M4 Manufacturers, Product Type & Application
- 3.7 Global Muscarinic Acetylcholine Receptor M4 Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Muscarinic Acetylcholine Receptor M4 Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Muscarinic Acetylcholine Receptor M4 Players Market Share by Revenue in 2025
- 3.8.3 2025 Muscarinic Acetylcholine Receptor M4 Tier 1, Tier 2, and Tier 3
4 Muscarinic Acetylcholine Receptor M4 Market by Type
- 4.1 Muscarinic Acetylcholine Receptor M4 Type Introduction
- 4.1.1 Tropicamide
- 4.1.2 VU-0467154
- 4.1.3 ANAVEX-273
- 4.1.4 Others
- 4.2 Global Muscarinic Acetylcholine Receptor M4 Sales by Type
- 4.2.1 Global Muscarinic Acetylcholine Receptor M4 Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Muscarinic Acetylcholine Receptor M4 Sales by Type (2021-2032)
- 4.2.3 Global Muscarinic Acetylcholine Receptor M4 Sales Market Share by Type (2021-2032)
- 4.3 Global Muscarinic Acetylcholine Receptor M4 Revenue by Type
- 4.3.1 Global Muscarinic Acetylcholine Receptor M4 Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Muscarinic Acetylcholine Receptor M4 Revenue by Type (2021-2032)
- 4.3.3 Global Muscarinic Acetylcholine Receptor M4 Revenue Market Share by Type (2021-2032)
5 Muscarinic Acetylcholine Receptor M4 Market by Application
- 5.1 Muscarinic Acetylcholine Receptor M4 Application Introduction
- 5.1.1 Amnesia
- 5.1.2 Cognitive Disorders
- 5.1.3 Psychosis
- 5.1.4 Others
- 5.2 Global Muscarinic Acetylcholine Receptor M4 Sales by Application
- 5.2.1 Global Muscarinic Acetylcholine Receptor M4 Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Muscarinic Acetylcholine Receptor M4 Sales by Application (2021-2032)
- 5.2.3 Global Muscarinic Acetylcholine Receptor M4 Sales Market Share by Application (2021-2032)
- 5.3 Global Muscarinic Acetylcholine Receptor M4 Revenue by Application
- 5.3.1 Global Muscarinic Acetylcholine Receptor M4 Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Muscarinic Acetylcholine Receptor M4 Revenue by Application (2021-2032)
- 5.3.3 Global Muscarinic Acetylcholine Receptor M4 Revenue Market Share by Application (2021-2032)
6 Global Muscarinic Acetylcholine Receptor M4 Sales by Region
- 6.1 Global Muscarinic Acetylcholine Receptor M4 Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Muscarinic Acetylcholine Receptor M4 Sales by Region (2021-2032)
- 6.2.1 Global Muscarinic Acetylcholine Receptor M4 Sales by Region (2021-2026)
- 6.2.2 Global Muscarinic Acetylcholine Receptor M4 Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Muscarinic Acetylcholine Receptor M4 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Muscarinic Acetylcholine Receptor M4 Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Muscarinic Acetylcholine Receptor M4 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Muscarinic Acetylcholine Receptor M4 Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Muscarinic Acetylcholine Receptor M4 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Muscarinic Acetylcholine Receptor M4 Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Muscarinic Acetylcholine Receptor M4 Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Muscarinic Acetylcholine Receptor M4 Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Muscarinic Acetylcholine Receptor M4 Revenue by Region
- 7.1 Global Muscarinic Acetylcholine Receptor M4 Revenue by Region
- 7.1.1 Global Muscarinic Acetylcholine Receptor M4 Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Muscarinic Acetylcholine Receptor M4 Revenue by Region (2021-2026)
- 7.1.3 Global Muscarinic Acetylcholine Receptor M4 Revenue by Region (2027-2032)
- 7.1.4 Global Muscarinic Acetylcholine Receptor M4 Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Muscarinic Acetylcholine Receptor M4 Revenue (2021-2032)
- 7.2.2 North America Muscarinic Acetylcholine Receptor M4 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Muscarinic Acetylcholine Receptor M4 Revenue (2021-2032)
- 7.3.2 Europe Muscarinic Acetylcholine Receptor M4 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Muscarinic Acetylcholine Receptor M4 Revenue (2021-2032)
- 7.4.2 Asia-Pacific Muscarinic Acetylcholine Receptor M4 Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Muscarinic Acetylcholine Receptor M4 Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Muscarinic Acetylcholine Receptor M4 Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Sumitomo Dainippon Pharma Co Ltd
- 8.1.1 Sumitomo Dainippon Pharma Co Ltd Company Information
- 8.1.2 Sumitomo Dainippon Pharma Co Ltd Business Overview
- 8.1.3 Sumitomo Dainippon Pharma Co Ltd Muscarinic Acetylcholine Receptor M4 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Sumitomo Dainippon Pharma Co Ltd Muscarinic Acetylcholine Receptor M4 Product Portfolio
- 8.1.5 Sumitomo Dainippon Pharma Co Ltd Recent Developments
- 8.2 AstraZeneca Plc
- 8.2.1 AstraZeneca Plc Company Information
- 8.2.2 AstraZeneca Plc Business Overview
- 8.2.3 AstraZeneca Plc Muscarinic Acetylcholine Receptor M4 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 AstraZeneca Plc Muscarinic Acetylcholine Receptor M4 Product Portfolio
- 8.2.5 AstraZeneca Plc Recent Developments
- 8.3 NeuroHealing Pharmaceuticals Inc
- 8.3.1 NeuroHealing Pharmaceuticals Inc Company Information
- 8.3.2 NeuroHealing Pharmaceuticals Inc Business Overview
- 8.3.3 NeuroHealing Pharmaceuticals Inc Muscarinic Acetylcholine Receptor M4 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 NeuroHealing Pharmaceuticals Inc Muscarinic Acetylcholine Receptor M4 Product Portfolio
- 8.3.5 NeuroHealing Pharmaceuticals Inc Recent Developments
- 8.4 Karuna Pharmaceuticals Inc
- 8.4.1 Karuna Pharmaceuticals Inc Company Information
- 8.4.2 Karuna Pharmaceuticals Inc Business Overview
- 8.4.3 Karuna Pharmaceuticals Inc Muscarinic Acetylcholine Receptor M4 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Karuna Pharmaceuticals Inc Muscarinic Acetylcholine Receptor M4 Product Portfolio
- 8.4.5 Karuna Pharmaceuticals Inc Recent Developments
- 8.5 Heptares Therapeutics Ltd
- 8.5.1 Heptares Therapeutics Ltd Company Information
- 8.5.2 Heptares Therapeutics Ltd Business Overview
- 8.5.3 Heptares Therapeutics Ltd Muscarinic Acetylcholine Receptor M4 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Heptares Therapeutics Ltd Muscarinic Acetylcholine Receptor M4 Product Portfolio
- 8.5.5 Heptares Therapeutics Ltd Recent Developments
- 8.6 Anavex Life Sciences Corp
- 8.6.1 Anavex Life Sciences Corp Company Information
- 8.6.2 Anavex Life Sciences Corp Business Overview
- 8.6.3 Anavex Life Sciences Corp Muscarinic Acetylcholine Receptor M4 Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Anavex Life Sciences Corp Muscarinic Acetylcholine Receptor M4 Product Portfolio
- 8.6.5 Anavex Life Sciences Corp Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Muscarinic Acetylcholine Receptor M4 Value Chain Analysis
- 9.1.1 Muscarinic Acetylcholine Receptor M4 Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Muscarinic Acetylcholine Receptor M4 Production Mode & Process
- 9.2 Muscarinic Acetylcholine Receptor M4 Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Muscarinic Acetylcholine Receptor M4 Distributors
- 9.2.3 Muscarinic Acetylcholine Receptor M4 Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst